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TNFα sensitizes hepatocytes to FasL-
induced apoptosis by NFκB-mediated Fas
upregulation
Laura Faletti1,2,3, Lukas Peintner 1, Simon Neumann1, Sandra Sandler1,3, Thomas Grabinger4,12, Sabine Mac Nelly5,
Irmgard Merfort3,6, Chun-Hao Huang7,13, Darjus Tschaharganeh7,14, Tae-Won Kang8,9,10, Florian Heinzmann8,9,10,
Luana D’Artista8,9,10, Ulrich Maurer 1,3, Thomas Brunner4, Scott Lowe7, Lars Zender8,9,10 and Christoph Borner1,3,11
Abstract
Although it is well established that TNFα contributes to hepatitis, liver failure and associated hepatocarcinogenesis via
the regulation of inﬂammation, its pro-apoptotic role in the liver has remained enigmatic. On its own, TNFα is unable
to trigger apoptosis. However, when combined with the transcriptional inhibitor GaLN, it can cause hepatocyte
apoptosis and liver failure in mice. Moreover, along with others, we have shown that TNFα is capable of sensitizing
cells to FasL- or drug-induced cell death via c-Jun N-terminal kinase (JNK) activation and phosphorylation/activation of
the BH3-only protein Bim. In this context, TNFα could exacerbate hepatocyte cell death during simultaneous
inﬂammatory and T-cell-mediated immune responses in the liver. Here we show that TNFα sensitizes primary
hepatocytes, established hepatocyte cell lines and mouse embryo ﬁbroblasts to FasL-induced apoptosis by the
transcriptional induction and higher surface expression of Fas via the NFκB pathway. Genetic deletion, diminished
expression or dominant-negative inhibition of the NFκB subunit p65 resulted in lower Fas expression and inhibited
TNFα-induced Fas upregulation and sensitization to FasL-induced cell death. By hydrodynamic injection of p65 shRNA
into the tail vein of mice, we conﬁrm that Fas upregulation by TNFα is also NFκB-mediated in the liver. In conclusion,
TNFα sensitization of FasL-induced apoptosis in the liver proceeds via two parallel signaling pathways, activation of
JNK and Bim phosphorylation and NFκB-mediated Fas upregulation.
Introduction
The death receptor Fas (CD95/APO-1) plays a central
role in maintaining liver homeostasis by contributing to
the removal of senescent, virus infected and cancer cells.
Engagement of Fas by its cognate ligand (FasL) triggers a
caspase-8/-3-dependent signaling cascade resulting in
apoptotic cell death. In particular, hepatocytes con-
stitutively express Fas1 and are susceptible to Fas-
mediated apoptosis in vitro2. Moreover, mice injected
with anti-Fas agonistic antibodies exhibit massive hepa-
tocyte apoptosis and die of fulminant liver failure within a
short time period3,4. Fas-mediated hepatocyte apoptosis is
a common pathological feature of several human liver
diseases5–11.
Activation of tumor necrosis factor receptor 1 (TNFR1),
unlike Fas, does not primarily lead to cell death in most
cell types12. Upon binding of TNFα to TNFR1, complex 1
is assembled leading to nuclear factor 'kappa-light-chain-
enhancer' of activated B-cells (NFκB) activation, which
induces a transcriptional program regulating inﬂamma-
tion, survival and proliferation. However, under speciﬁc
conditions, engagement of TNFR1 leads to the formation
complex 2 or the necrosomal complex, which foster cell
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death by apoptosis or necroptosis, respectively13. The
transcription factor NFκB plays a crucial role in main-
taining the balance between survival and death because of
its ability to induce various anti-apoptotic and inﬂam-
matory proteins14–17. Therefore, an acute treatment of
mice with TNFα only provokes hepatocyte cell death and
liver injury when combined with transcriptional arrest
such as the co-treatment with actinomycin D (ActD) or
D-galactosamine (GaLN)18. The administration of lipo-
polysaccharide (LPS) (which induces TNFα production)
to GaLN-sensitized mice has therefore been widely used
as an experimental model for endotoxic shock19–21. In
this model, liver injury indeed depends on the action of
TNFα.
The initial wave of hepatotoxicity is often insufﬁcient to
cause fatal liver injury while a second step involving
activation of the immune system eventually exacerbates
tissue damage causing liver failure. TNFα, which is mainly
produced by activated macrophages during inﬂammation,
has been implicated as an important pathogenic mediator
during liver diseases. Indeed, increased levels of TNFα
have been found in the serum and livers of patients with
chronic and acute hepatitis22–24. Moreover, Minagawa
and colleagues unraveled a cooperative contribution of
Fas and TNFR1 to chronic alcohol-induced liver injury25.
This is in agreement with reports showing that fulminant
liver injury induced by the injection of agonistic anti-Fas
antibody is suppressed in TNFR1 defective mice26 and
Fig. 1 TNFα pretreatment enhances FasL-induced apoptosis. a Caspase-3/-7 activity in total cell lysates of primary mouse hepatocytes, treated
with FasL alone for 0–5 h (-TNFα) or pretreated with TNFα for 14 h, followed by treatment with FasL for 0–5 h. b 7-AAD staining of primary
hepatocytes treated as under (a). The percentage (%) of cells in the subG1 cell cycle stage (apoptotic cells) are shown. c Morphology of living and
apoptotic primary hepatocytes treated with TNFα and FasL as indicated, observed under an inverted phase-contrast microscope, scale bar: 100 µm.
Caspase-3/-7 activity in total cell lysates of (d) Hepa1-6 or (e) AML12 cell lines either untreated, treated with TNFα or FasL alone or pretreated
with TNFα for 14 h followed by FasL for 4 h. a.u. arbitrary units. (a, b) Values represent the means of at least three independent experiments ± SD.
(d, e) Data were obtained from four (d) or three (e) independent experiments; the horizontal line represents the mean
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basal resistance of lung ﬁbroblasts to Fas-induced apop-
tosis could be overcome by sensitization with TNFα27.
Consistent with these ﬁndings, we previously reported
that TNFα can enhance FasL-mediated cytotoxicity in
isolated primary mouse hepatocytes via a JNK/Bim-
dependent pathway28. However, c-Jun N-terminal
kinase (JNK) inhibition or Bim deletion did not full-
y rescue the cells from TNF-induced apoptosis sensiti-
zation indicating there must be another crosstalk
between TNFα- and FasL-induced signaling, which
increases hepatocyte cell death and contributes to liver
diseases.
Previous studies revealed that TNFα is able to upregu-
late Fas in mouse embryonic ﬁbroblasts29, acute myeloid
leukemia cell lines30 and neuroblastoma cells31. A binding
site for the transcription factor NFκB was described in the
Fas promoter, which regulates activation-dependent Fas
expression in lymphocytes32. NFκB was also found to
mediate transcriptional activation of Fas in hepatocytes
during adenoviral hepatitis33 although increased Fas sur-
face expression and higher sensitivity to FasL-induced
apoptosis were not examined.
In the present study, we found that in addition to
activating the JNK/Bim pathway, TNFα sensitizes to FasL-
induced cell death of hepatocytes by upregulating Fas
surface expression through an NFκB-mediated transcrip-
tional induction of the Fas gene. This mechanism is also
observed in the liver in vivo after treating mice with LPS
or TNFα indicating that TNFα does not only engage
NFκB to induced inﬂammatory and survival processes in
the liver, but also to sensitize the organ to potential
damage by FasL.
Results
TNFα enhances FasL-mediated apoptosis in hepatocytes
We previously reported that pretreatment of primary
mouse hepatocytes with TNFα for 12 h signiﬁcantly
enhanced FasL-induced caspase-3 activation (Fig. 1a)28
and apoptosis (Fig. 1b, c). This was also observed in
mouse hepatoma Hepa1-6 cells, immortalized mouse
AML12 hepatocytes and primary and SV40-immortalized
mouse embryo ﬁbroblasts (MEFs). They all exhibited
increased caspase-3 activity (Fig. 1d, e and Supplementary
Figure 1b, c) and apoptosis (Supplementary Figure 1a)
Fig. 2 TNFα treatment leads to increased cell surface Fas expression through transcriptional induction. Anti-Fas or anti-cleaved caspase-3
western blot analysis of whole lysates of a primary mouse hepatocytes, b Hepa1-6 or c AML12 cells, either untreated, treated with TNFα or FasL alone
or pretreated with TNFα for 14 h before adding FasL for 4 h. Actin serves as loading control. Cell surface expression of Fas measured by FACS analysis
using the anti-mFas antibody (conjugated to Alexa Fluor 488) signiﬁcantly increases after 14 h of TNFα treatment in d primary mouse hepatocytes,
e Hepa1-6 or f AML12 cells. RT-qPCR analysis of Fas mRNA (shown as fold change normalized to L32 mRNA) of g primary mouse hepatocytes or
h Hepa1-6 cells shows that Fas gene transcription increases after TNFα treatment for 2 h or 14 h. a.u. arbitrary units. (d-h) Data were obtained
from ﬁve, four or three independent experiments as indicated; the horizontal line represents the mean
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when they were treated with TNFα 14 h before
FasL addition for 4 h. Importantly, TNFα itself did
neither induce caspase-3 activity nor apoptosis in any cell
type investigated (Fig. 1c–e and Supplementary
Figure 1a–c). Thus, TNFα sensitization of FasL-induced
apoptosis is a general phenomenon observed in different
cell types.
Fas is upregulated in response to TNFα treatment
The apoptosis sensitization effect of TNFα was depen-
dent on the preincubation of TNFα for >2 h before FasL
addition28. A simultaneous cellular stimulation with
TNFα and FasL did not enhance Fas-induced apoptosis.
This indicated that some factor was needed to be induced
before the cells became more sensitive to FasL-induced
Fig. 3 Fas is induced in hepatocytes in the liver after TNFα or LPS injection into mice. a Western blot analysis of Fas levels in total liver lysates
from two different mice injected with PBS or TNFα for 14 h. bWestern blot analysis of Fas expression in the cytosol and membrane fractions of whole
liver extracts from mice injected with PBS, TNFα or LPS for 14 h. Actin and tubulin serves as loading markers, E-cadherin as marker for plasma
membrane proteins. c FACS analysis of Fas cell surface expression on hepatocytes freshly isolated from the liver of mice injected with PBS or TNFα for
14 h. Data were obtained from ﬁve independent experiments. The horizontal line represents the mean. d Anti-mFas DAB (top panels, scale bar:
75 µm) or red immunoﬂuorescence (lower panels, scale bar: 50 µm) staining of liver slices from mice injected with PBS (left panels) or TNFα (right
panels) for 14 h. Nuclei are stained with DAPI in the lower panels. Arrows point to the increased surface Fas expression after TNFα treatment
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cell death. As TNFα was reported to increase Fas receptor
expression in other cell lines29–33, we hypothesized that
this mechanism may also play a role in hepatocytes.
Indeed, we observed increased Fas protein expression
after 14 h of TNFα treatment in primary, Hepa1-6 and
AML12 hepatocytes (Fig. 2a–c). By contrast, Fas levels
diminished after FasL and TNFα/FasL treatments, prob-
ably due to endosomal degradation after receptor activa-
tion and/or apoptosis induction as seen by increased
caspase-3 processing (Fig. 2a, b). Quantitative reverse
transcriptase-PCR analysis revealed that increased Fas
expression by TNFα was due to increased Fas gene
transcription, which was already maximal after 2 h of
TNFα treatment (Fig. 2g, h). Moreover, we could show by
ﬂuorescence-activated cell sorting (FACS) analysis using
an anti-Fas antibody detecting the extracellular domain of
Fas that two- to threefold more Fas was expressed on the
surface of primary hepatocytes (Fig. 2d), Hepa1-6 (Fig. 2e)
and AML12 (Fig. 2f) cells after 14 h of TNFα treatment.
Fas mRNA (Supplementary Figure 2a), total protein
(Supplementary Figure 1d, e) and surface expression
levels (Supplementary Figure 2b) also increased after
TNFα treatment in primary and immortalized MEFs.
Injection of TNFα or LPS trigger Fas upregulation in the
liver
To investigate if TNFα also triggered increased Fas
surface expression on hepatocytes in vivo, we injected
mice with 200 µg of TNFα/kg of body weight, 2 mg of
LPS/kg of body weight or phosphate-buffered saline (PBS)
(as control) and sacriﬁced the animals after 14 h. We
noted increased Fas protein expression in total liver
lysates from TNFα-treated as compared with PBS-treated
animals (Fig. 3a). Most of the Fas protein was found in the
membrane fraction (Fig. 3b). Similarly, LPS was capable of
inducing membrane-bound Fas in hepatocytes in vivo.
We then isolated primary hepatocytes from these mice by
collagenase perfusion and subjected them to FACS ana-
lysis using an antibody recognizing the extracellular
domain of Fas. As shown in Fig. 3c, surface expression
of Fas signiﬁcantly increased on hepatocytes from
TNFα-treated as compared with PBS-treated animals.
Concomitantly, immunohistochemical analysis on liver
sections from TNFα-treated mice revealed an enhanced
plasma membrane staining of Fas on hepatocytes
(Fig. 3d).
Knockdown of p65 reduces Fas expression and abrogates
apoptosis sensitization by TNFα
It is well known that TNFα activates the NFκB signaling
pathway leading to the transcriptional induction of pro-
survival and pro-inﬂammatory genes. However, previous
studies also indicated the induction of apoptotic genes
such as Fas by NFκB31,33. As expected, the NFκB pathway
was quickly activated within 10min of TNFα treatment in
primary mouse hepatocytes (Supplementary Figure 3a)
and Hepa1-6 cells (Supplementary Figure 3c) as shown by
the phosphorylation and subsequent degradation of the
NFκB inhibitor IκBα and the enhanced phosphorylation
of the NFκB subunit p65. At 6–8 h posttreatment with
TNFα, we also observed a time-dependent increase in
total Fas protein expression in both cell lines (Supple-
mentary Figure 3b, c). To elucidate whether Fas was
transcriptionally activated by NFκB, we knocked down the
expression of the essential p65 subunit of NFκB. For that
purpose, we used the microRNA (miR)-adapted small
hairpin (sh) RNA (shRNA-miR) system, in which syn-
thetic shRNAs targeting p65, Fas and Renilla luciferase (as
control) were embedded in the context of an optimized
variant of the existing miR-30 endogenous microRNA
(miR-E)34. The knockdown efﬁciency of different
p65 shRNAs at single-copy conditions was previously
validated35, and that of Fas shRNAs is shown in Supple-
mentary Figure 4a. The most potent shRNAs were
then chosen to infect Hepa1-6 and AML12 cells.
The knockdown efﬁciency of both p65 NFκB and Fas
shRNAs was up to 70% (Fig. 4b, c and Supplementary
Figure 4b, d). Importantly, downregulation of p65 was
accompanied by reduced transcription of canonical
NFκB-target genes IκBα and Bcl-xL (Supplementary Fig-
ure 4d). Also, FasL- and TNFα/FasL-induced caspase-3
activity was largely diminished in the presence of shFas
(Supplementary Figure 4c) indicating that the shRNAs
effectively reduced the biological function of their
respective targets.
Although TNFα still induced a fourfold increase of Fas
mRNA in shRenilla control Hepa1-6 cells as compared
with untreated cells, this effect was entirely ablated when
p65 expression was downregulated by p65 shRNA
(Fig. 4a). Similarly, Fas protein levels were not augmented
by TNFα upon p65 reduction in both Hepa1-6 (Fig. 4b)
and AML12 cells (Fig. 4c). This was also the case for Fas
surface expression. Introduction of shp65 into Hepa1-6
and AML12 cells completely prevented the increase of Fas
protein on the cell surface after 14 h of TNFα treatment
(Fig. 4d, e). In both cell lines, the failure to augment
surface Fas expression diminished TNFα sensitization of
FasL-induced caspase-3 activation to the level seen with
FasL alone (Fig. 4f, g) indicating that the apoptosis sen-
sitizing effect of TNFα required the NFκB-mediated
transcriptional induction and surface expression of Fas.
Interestingly, even in the absence of TNFα, surface Fas
expression and FasL-induced caspase-3 activity was
diminished after p65 knockdown (Fig. 4b–g) suggesting
that Fas expression was controlled by NFκB even under
steady-state conditions.
To further substantiate the role of p65 NFκB in the Fas
upregulation and apoptosis sensitization by TNFα, we
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used MEF cell lines either deﬁcient of p65 (p65 KO) or
expressing a dominant-negative (DN) form of the NFκB
inhibitor IκBα, which cannot be phosphorylated and
subsequently degraded. 3T9- or SV40-transformed wild-
type (WT) MEFs showed a marked increase in mRNA
(Supplementary Figure 2a), protein (Supplementary Fig-
ure 2d) and surface expression of Fas (Supplementary
Figure 2b) and were sensitized to FasL-induced caspase-3
activation after TNFα (pre-) treatment for 14 h (Supple-
mentary Figure 2c). All these effects were drastically
diminished or even ablated when p65 was missing (p65
KO) or inhibited by IκBαDN. Again, total Fas protein and
surface expression were already reduced in IκBαDN cells
or p65 KO in the absence of TNFα.
HepG2 cells do not upregulate Fas in response to TNFα
and are therefore not sensitized to FasL-induced apoptosis
To corroborate the connection between TNFα-induced
Fas upregulation and sensitization to FasL-induced
apoptosis, we performed our studies in the human
Fig. 4 Knockdown of p65 decreases Fas expression and reduces TNFα-mediated sensitization to FasL-induced apoptosis. a RT-qPCR analysis
of Fas mRNA of Hepa1-6 cells stably expressing Renilla or p65 shRNAs, untreated or treated with TNFα for 2 h. b Anti-p65 and anti-Fas western blot
analysis of wild-type (Wt), shRenilla or shp65 Hepa1-6 cells, untreated or treated with TNFα for 14 h. Tubulin serves as loading control. c The same
analysis as in b but in AML12 cells. FACS analysis of Fas cell surface expression on shRenilla or shp65 Hepa1-6 (d) or AML129 (e) cells, untreated
or treated with TNFα for 14 h. Caspase-3/-7 activity in total cell lysates of shRenilla or shp65 Hepa1-6 cells (f) or AML12 cells (g). a.u. arbitrary units.
(a, d-g) Values represent the means of at least three independent experiments ± SD
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hepatoblastoma cell line HepG2. Surprisingly, TNFα
treatment did not sensitize HepG2 cells to FasL-induced
apoptosis (Fig. 5a). Total Fas protein and surface
expression were already high in HepG2 cells and TNFα
was incapable of further increasing its level (Fig. 5b, c),
despite normal activation of NFκB (Fig. 5c). Moreover,
knockdown of p65 by shRNA expression only slightly
diminished the amount of cellular Fas (Fig. 5d, e) indi-
cating that in this cancer cell line Fas expression was not
under the control of NFκB and hence TNFα was unable to
sensitize the cells to FasL-induced apoptosis. These
results indicate that TNFα sensitization to FasL-induced
apoptosis is tightly linked to Fas upregulation.
Knockdown of p65 in vivo reduces TNFα-mediated Fas
upregulation in the mouse liver
To test the role of NFκB for TNFα-induced Fas upre-
gulation in vivo, a recombinant Sleeping Beauty (SB)
transposon vector harboring p65, Renilla (negative con-
trol) or Fas shRNAs and a vector containing a transposase
were combined and co-injected into mice by hydro-
dynamic tail vein injection. This procedure allows
the rapid delivery of the shRNAs through the lateral
tail vein into the liver and their selective uptake by
hepatocytes36. The transient expression of the transposase
facilitates the integration of the transposons into the
hepatocytes DNA allowing stable transgene expression.
Due to coupling green ﬂuorescent protein (GFP) to the
shRNA, hepatocytes expressing the respective shRNA can
be easily monitored by green ﬂuorescence microscopy.
Five days after hydrodynamic tail vein injection with the
different shRNAs, the mice were injected intraperitoneally
with PBS or TNFα and sacriﬁced after 14 h. As shown in
Supplementary Figure 5a, about 5–10% of hepatocytes
had taken up the shRNAs (GFP-positive hepatocytes).
Anti-p65 immunoﬂuorescence analysis of liver slices of
mice injected with p65 shRNA revealed that the GFP-
positive cells exhibited an efﬁcient downregulation of p65
NFκB expression (Supplementary Figure 5a, comparing
upper and lower panels). As previously shown (Fig. 3d),
TNFα treatment for 14 h increased Fas surface levels on
hepatocytes in vivo (Supplementary Figure 5b). However,
by this analysis it was difﬁcult to determine if Fas surface
expression was diminished in shp65/GFP-positive hepa-
tocytes due to the proximity of high surface Fas expres-
sing, GFP-negative hepatocytes (Supplementary
Fig. 5 TNFα treatment does neither upregulate Fas nor enhance FasL-induced apoptosis in HepG2 cells. a Caspase-3/-7 activity in total lysates
of HepG2 cells, either untreated, treated with TNFα or FasL alone or pretreated with TNFα for 14 h before adding FasL for 4 h. b FACS analysis of
surface Fas expression in HepG2 cells treated with TNFα for 14 h. a.u. arbitrary units. c Anti-phospho-p65, anti-IκBα and anti-Fas western blot analysis
of total extracts of HepG2 treated with TNFα for up to 840min. d Anti-p65 and anti-Fas western blot analysis of total extracts of shRenilla or shp65
HepG2 cells. Tubulin serves as loading controls. e FACS analysis of Fas surface expression using anti-hFas conjugated to APC on shRenilla or shp65
HepG2 cells. (a, b, e) Data were obtained from three or two independent experiments as indicated. The horizontal line represents the mean
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Figure 5b). We therefore isolated hepatocytes from
Renilla, p65 or Fas shRNA tail-injected animals after
TNFα- or PBS treatment and subjected them to FACS
analysis using GFP (green) and anti-Fas-APC (red)
ﬂuorescence analysis. Consistent with our previous ﬁnd-
ings, the GFP-positive hepatocytes from mice injected
with shRenilla control plasmids showed a signiﬁcant
increase in Fas surface levels after TNFα treatment as
compared with those isolated from PBS-treated animals
(Fig. 6a, gray bars). This was not the case for GFP-positive
hepatocytes carrying the shp65 plasmid. Here TNFα
treatment did not achieve a further upregulation of Fas
surface expression as compared with PBS-treated animals
(Fig. 6a, black bars). Of note, we found less GFP-positive
cells in the liver of shp65-injected as compared with
shRenilla-injected or shFas-injected mice (Fig. 6b), most
likely because the lack of p65 may be detrimental to the
survival of liver cells and therefore lead to their cell death.
In summary, we could prove that NFκB contributes to Fas
surface upregulation in response to TNFα not only
in vitro but also in murine livers in vivo.
Discussion
We previously reported that cell pretreatment with
TNFα for a minimum of 12 h sensitized murine primary
hepatocytes to FasL-induced apoptosis via JNK activation
and phosphorylation/activation of Bim28. Here we
uncover an additional mechanism for this sensitization.
We ﬁnd that primary murine hepatocytes, as well as
established hepatocyte and embryo ﬁbroblast cell lines
upregulate Fas in response to TNFα in an NFκB-
dependent manner. The p65 subunit of NFκB was not
only required for TNFα-induced Fas transcription, but
also for Fas protein and Fas cell surface expression. Fas
transcription even seemed to depend on p65 in unsti-
mulated cells (in the absence of TNFα) suggesting that
p65 might be the major transcription factor driving Fas
surface expression in hepatocytes and other cells.
Importantly, this mechanism also occurred in the liver
in vivo, as tail vein injection of mice with shp65 dimin-
ished TNFα-induced upregulation of Fas surface expres-
sion on isolated primary hepatocytes. Although we could
clearly show that p65-mediated Fas upregulation sensi-
tized hepatocytes and ﬁbroblasts for FasL-induced apop-
tosis in vitro, this was difﬁcult to conﬁrm in vivo. Mice
injected with FasL or agonistic anti-Fas antibodies die
within 4 h due to liver failure. A pre-injection of mice with
TNFα or LPS is expected to kill these animals even faster,
a condition that cannot be approved under the animal
experiment regulations in Germany.
Our ﬁndings partly explain studies by other authors in
the past. For example, Costelli and colleagues reported in
2003 that mice deﬁcient in TNFR1 and TNFR2 were
resistant to a single dose of anti-Fas that was lethal for
TNFR-expressing animals26. They claimed that treatment
with anti-Fas somehow engaged the TNFα/TNFR system,
which synergized with Fas-mediated signals to cause ful-
minant liver injury. In agreement with these results,
Matsuki and colleagues provided evidence that injection
of anti-Fas antibodies triggered the production of TNFα
by Kupffer cells in the liver37. Moreover, full protection
from anti-Fas-induced mortality could only be achieved
by pretreatment with neutralizing antibodies against Fas
and TNFR1. Furthermore, in an experimental mouse
model of alcohol-induced liver injury, Minagawa and
colleagues showed that chronic alcohol feeding led to an
increase in NKT cells in the liver that mediated hepato-
cyte cell death via the Fas pathway. Also here TNFα
seemed to play a crucial role as TNFR1-deﬁcient animals
were protected from Fas-induced liver injury25. Besides
the direct alcohol injury on the liver, excessive alcohol
uptake impairs the gut barrier function leading to elevated
endotoxin levels in the liver. In this scenario, LPS sti-
mulates the release of TNFα by local macrophages
Fig. 6 Knockdown of p65 in hepatocytes in vivo decreases TNFα-mediated Fas upregulation. FACS analysis of primary hepatocytes isolated
from mice tail vein injected with plasmids carrying the p65, Fas or Renilla shRNAs for 5 days and treated with PBS or TNFα for 14 h, stained with anti-
Fas-APC or isotype-APC. a GFP-positive cells, which incorporated the shRenilla (gray bars) or p65 shRNAs (black bars) were separately gated to
calculate the mean ﬂuorescence of Fas surface expression; a.u. arbitrary units. b Percentage of isolated, GFP-positive hepatocytes that incorporated
the respective injected shRNAs (shRenilla, black; shp65, gray; shFas, dark gray). Values represent the means of at least three mice ± SD.
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(Kupffer cells), which then acts on hepatocytes to upre-
gulate Fas and amplify FasL-induced cell death. In this
context, it is reasonable to postulate that under certain
conditions of liver inﬂammation, TNFα-mediated Fas
upregulation may be a critical factor for the ampliﬁcation
of hepatocyte apoptosis in vivo. In addition, our immu-
nohistochemistry (IHC)/immunoﬂuorescence analysis
suggest that TNFα may not only trigger the upregulation
of the Fas protein but also its transport from intracellular
compartments to the cell surface. It has been demon-
strated that in unstimulated cells, Fas is mainly stored in
the cytoplasm particularly in the Golgi38,39.
TNFα potently activates NFκB via phosphorylation-
dependent, proteasomal degradation of its inhibitor IκB.
Active NFκB then induces the expression of a variety of
anti-apoptotic and pro-inﬂammatory genes17,40. Para-
doxically, NFκB was also reported to inﬂuence the
expression of pro-apoptotic genes such as ligands and
receptors of the TNF superfamily41 but until now the
effect of NFκB activation on the apoptosis sensitivity of
primary hepatocytes has not yet been investigated. In
contrast to NFκB activation (based on IκB phosphoryla-
tion/degradation and p65 phosphorylation), which occurs
within 10–30min of TNF treatment, Fas upregulation and
concomitant sensitization to FasL-induced apoptosis
takes 6–12 h to proceed (Supplementary Figure 3). Two
distinct waves of NFκB recruitment to target promoters
have been reported: a fast recruitment to constitutively
and immediately accessible promoters and a late recruit-
ment to promoters requiring stimulus-dependent mod-
iﬁcations in chromatin structure to make NFκB sites
accessible42. NFκB-regulated pro-apoptotic genes like Fas
may be under the control of late recruitment promoters
explaining the delayed transcriptional Fas upregulation
observed in response to TNFα in our cellular systems. An
example that integrates the protective role of NFκB
activity and the enhancement of cell sensitivity to apop-
tosis may be found in pre-malignant senescent hepato-
cytes. Senescent cells constitutively activate NFκB, which
leads to the so-called senescence-associated secretory
phenotype43. This phenotype includes the release of
inﬂammatory cytokines, which serves to recruit T lym-
phocytes and NK cells for the clearance of the senescent
cells. It may be possible that this constitutive NFκB acti-
vation contributes to overexpression of Fas that helps to
eliminate the senescent cells by FasL-expressing T lym-
phocytes. As FasL is mainly produced by activated
immune cells, hepatocytes and other cells expressing high
levels of Fas, either in a constitutive or TNFα-inducible
manner, are not immediately killed but only when
recognized and/or attacked by immune cells.
In our in vivo knockdown experiments, we found a
smaller increase of Fas surface expression in GFP+ cells
from p65 shRNA injected mice as compared with
shRenilla injected mice after TNFα treatment. This ten-
dency is comparable to our in vitro results. However, the
yield of isolating GFP+ primary hepatocytes from the
shp65 injected mice was signiﬁcantly lower compared
with the shRenilla and shFas-injected animals. This indi-
cates that knocking down p65 could have been cytotoxic
to hepatocytes in vivo. This would be consistent with the
previous ﬁnding that NFκB is an important survival factor
in liver cells as mice lacking the p65 subunit of NFκB
exhibit embryonic lethality at days 15–16 of gestation,
accompanied by massive destruction of liver via apopto-
sis44. In this respect, it was advantageous for our studies
that p65 shRNA was not expressed in all hepatocytes after
tail vein injection and did not completely knockout the
expression of p65 in these cells.
TNFα is known to induce both NFκB and JNK signaling.
Although JNK has been mostly associated with apoptotic
outcome, NFκB activation predominantly ensures cell
survival. We previously published that JNK activation and
subsequent JNK-mediated Bim phosphorylation at three
sites enhances the pro-apoptotic activity of Bim toward
Bax/Bak activation and contributes to TNFα sensitization
of FasL-induced apoptosis28. However, blocking this
pathway by JNK inhibition or genetic ablation of Bim did
not fully inhibit the TNF sensitization. We now show that
also NFκB-mediated FasL upregulation contributes to this
process. Thus, NFκB does not only control hepatocytes
survival but also their sensitivity of FasL-induced cell
death. Our ﬁnding will further enlarge the molecular
understanding of various types of liver diseases and will
eventually contribute to the development of novel
therapies.
Materials and methods
Cell lines
WT and p65-/- embryonic ﬁbroblasts (MEF) immorta-
lized with SV40 T antigen were kindly provided by
Andreas Strasser (WEHI, Melbourne, Australia),
HEK293T and HepG2 (ATCC, Manassas, VA, USA),
mouse hepatoma Hepa1-6 and 3T3 MEFs were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) high glu-
cose medium, supplemented with 10% fetal calf serum and
1% penicillin/streptomycin. AML12 mouse hepatocytes
were cultured in William's medium supplemented with
100 nM dexamethasone, 2 mM L-glutamine, insulin 1 µM,
10% fetal calf serum and 1% penicillin/streptomycin.
Cell treatments
Primary mouse hepatocytes were incubated with med-
ium containing TNFα (20 ng/ml, Peprotech, London, UK)
or not for 14 h. The cells were either harvested for Fas
expression analysis, or Fc-FasL (20 ng/ml, Adipogen,
Epalinges, Switzerland) was added to measure cell death.
The other cell lines were plated on six-well plates at a
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density of 2.5 × 105 cells/well 1 day before treatment. On
the next day, they were treated in the same way as primary
mouse hepatocytes. HepG2 cells were treated with human
instead of mouse TNFα.
Animal studies
All C57BL/6 mice were kept under speciﬁc pathogen-
free conditions and a controlled humidity and lighting
schedule with a 12-h light/dark period and free access to
food (regular mouse chow) and water. Mouse experi-
ments were performed in Freiburg, Tübingen and New
York, complied with animal experimentation regulations
of Germany and the US and were approved by the Ethics
Review Committee of the regional Council in Tübingen/
Freiburg and the Memorial Sloan Kettering Cancer Cen-
ter (MSKCC) Animal Care and Use Committee in New
York City.
Isolation and culture of primary mouse hepatocytes
Primary mouse hepatocytes were isolated from 8 to
14 weeks old male C57BL/6 mice (Jackson Laboratories,
Bar Harbor, ME, USA) by collagenase perfusion as
reported45. Brieﬂy, the mice were anesthetized by intra-
peritoneal (i.p) injection with 5 mg 10% ketamine hydro-
chloride (Ketanest, Pﬁzer, NY, USA) and 1 mg 2% xylazine
hydrochloride (Rompun, Bayer, Leverkusen, Germany)
per 100 g of body weight. The abdominal cavity was
opened and the portal vein cannulated with a 24G
catheter connected to a peristaltic pump through a silicon
tube. The liver was perfused with Hanks solution I
(Hanks, 2 mM EGTA, 0.1% glucose) for 2 min at a ﬂow
rate of 8 ml/min. Afterward, Hanks solution II was per-
fused (Hanks, 5 mM CaCl2, 0.3 mg/ml collagenase CLS II)
for 5–7min and the liver was removed from the mouse.
The liver capsule was taken with forceps and carefully
shaken until the hepatocytes were released. The cells were
ﬁltered through a 70 μM cell strainer and washed in
William´s medium supplemented with 100 nM dex-
amethasone, 2 mM L-glutamine, 1 µM insulin, 10% fetal
calf serum and 1% penicillin/streptomycin (attachment
medium) twice (50 × g for 2 min centrifugation). The
hepatocyte suspension was either used right after isolation
(e.g., Fas receptor analysis) or plated (1 × 106 cells/well) on
rat tail collagen I-coated six-well plates in attachment
medium. After allowing the cells to attach for 4 h, they
were washed and further incubated in William´s medium
supplemented with 2 mM L-glutamine, 10% fetal calf
serum and 1% penicillin/streptomycin. Primary hepato-
cytes were used for experiments within 2–3 days after
isolation.
RNA extraction and RT-qPCR
Total RNA was isolated from non-treated and TNFα-
treated cells using the TRIZOL reagent (Thermo Fisher
Scientiﬁc, Darmstadt, Germany). Reverse transcription
was performed using 2 µg of total RNA (Invitrogen
Superscript First Strand Synthesis Kit, Invitrogen, Karls-
ruhe, Germany) plus random hexamers. Quantitative PCR
(qPCR) was performed in 96-well plates using 12.5 µl
Mesa Blue qPCR Mix (including Hotstar meteor Taq
polymerase), 0.5 µl of each forward and reverse primer for
the candidate gene (10 µM stock), 9.5 µl of distilled H2O
and 2 µl of the reverse-transcribed complementary DNA
(cDNA) per well. The housekeeping gene L32 was used
for normalization. For each cDNA sample, triplicates were
measured with the two primer pairs (gene of interest and
housekeeping gene). The plate was sealed with adhesive
foil, spun down at 1000 rpm for 1 min and then subjected
to the PCR reaction in a Biorad MyiQ Real-time PCR
machine (Bio-Rad, Munich, Germany).
Preparation of whole-cell lysates
For the preparation of whole-cell lysates, the cells were
harvested, washed once with ice‐cold PBS and then lysed
in extraction buffer [20 mM Tris–HCl, pH 7.5, 150mM
NaCl, 1% Triton X‐100, 5 mM EDTA, 1 × protease inhi-
bitor cocktail complete (Roche, Penzberg, Germany),
MG132 (20 μM, Alexis Biochemicals, Laussane, Switzer-
land), phosphatase inhibitor cocktail 1 (1:50, Sigma‐
Aldrich)] on ice for 15min. Lysates were centrifuged at
13,000 rpm for 5 min at 4 °C. For the subcellular fractio-
nation of liver samples, a piece of liver was cut and
washed several times in PBS to eliminate the red blood
cells. The tissue was ﬁrst homogenized in RIPA buffer+
0.2% NP-40 for 10min using a Dounce homogenizer on
ice. The extract was centrifuged at 20,000 g for 20 min and
the supernatant was kept as the cytosolic fraction. The
pellet was further lysed in RIPA buffer+ 1% sodium
dodecyl sulfate (SDS) for 30 min on ice and then cen-
trifuged at 20,000 g for 20 min. The supernatant was
considered as solubilized membrane fraction. The protein
concentration was determined using the bisinchoninic
acid protein assay (BCA, Pierce Thermo Scientiﬁc,
Darmstadt, Germany).
Immunoblot analysis and antibodies
For western blot analysis, the cellular extracts were
solubilized in 3× Laemmli buffer consisting of 1% SDS
and boiled for 5 min at 95 °C. Equal protein amounts
(30–80 μg) were separated on SDS–polyacrylamide gel
electrophoresis (12.5–15% gels) and transferred to nitro-
cellulose membranes. Antibody detection was accom-
plished using the enhanced chemiluminescence method
(Thermo Fisher Scientiﬁc, Darmstadt, Germany) and
developed either with the Fusion SL Imager (Vilber
Lourmat, Eberhardzell, Germany) or the Curix60 pro-
cessor (Agfa healthcare, Bonn, Germany). The following
antibodies were used in 3% milk/TBS–Tween (0.1%): anti-
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mFas (1:1000, Santa Cruz Biotechnology, Dallas, TX,
USA), anti-actin (1:40,000, MP Biomedicals, Eschwege,
Germany), anti-tubulin (Bio-Rad, Munich, Germany),
anti-E-cadherin (BD Transduction laboratories, Heidel-
berg, Germany), anti-hFas, anti-p65, anti-phospho-p65,
anti-IκBα, anti-phospho-IκBα, anti-cleaved caspase-3 and
anti-Bcl-xL (Cell Signaling, Leiden, The Netherlands).
Cell death assays
To determine the enzymatic activity of effector caspase-
3 and caspase-7, 40 µg of a whole-cell lysate was incubated
with the ﬂuorogenic substrate DEVD‐AMC (60 μM, Enzo
Life Science, Lausen, Switzerland) in caspase-3 activity
buffer (100 mM Hepes, pH 7.5, 10 mM dithiothreitol).
Right afterward, ﬂuorescence (460 nm) was measured at
1-min intervals during 30min (37 °C, Tecan Inﬁnite M200
microplate reader, Crailsheim, Germany). The relative
caspase activity (arbitrary units) was calculated as the
slope of the linear regression between the absorbance and
the time. Cell death in Hepa1-6 and MEFs cells was fur-
ther determined by FACS analysis (FACSDiva, BD Bios-
ciences, Heidelberg, Germany) using the Annexin-V/7-
AAD detection system. Cells were harvested and washed
in Annexin binding buffer (10 mM Hepes, 140mM NaCl,
2.5 mM CaCl2, pH 7.4) and stained for 15min in the same
buffer with Annexin-V-FITC (1 µg/ml, produced in-
house). The DNA dye 7-aminoactinomycin D (7-AAD) (1
µg/ml, Thermo Fisher Scientiﬁc, Darmstadt, Germany)
was added right before measurement. In the case of pri-
mary mouse hepatocytes, viability was assessed by DNA
content analysis, considering the subG1 peak as the dying
population. For that purpose, the hepatocytes were ﬁxed
with 70% ethanol, washed with PBS and then stained with
a solution of propidium iodide (PI) (20 µg/ml, Sigma-
Aldrich, Taufkirchen, Germany) containing RNAase (200
µg/ml, Qiagen, Hilden, Germany).
shRNA design and cloning
De novo shRNAs predictions for p65 and Fas targeting
common regions of all known transcript variants were
obtained using the SplashRNA algorithm. The existing
miR-30 p65-1 shRNA was converted to miR-E by PCR
ampliﬁcation using the miRE-Xho-short-fw (5′-
AGAAGGCTCGAGAAGGTATATTGC-3′) and miR-E
EcoPlasmid-rev (5′-GCTCGAATTCTAGCCCCTT
GAAGTCCGAGG-3′) primers. For de novo generation of
miR-E shRNAs, 97-mer oligonucleotides (IDT Ultramers,
Coralville, IA, USA) coding for p65 and Fas shRNAs were
PCR ampliﬁed using the primers miRE-Xho-fw (5′-
TGAACTCGAGAAGGTATATTGCTGTTGACAGTG
AGCG-3′) and miRE-EcoOligo-rev (5′-TCTCGAATTC
TAGCCCCTTGAAGTCCGAGGCAGTAGGC-3′). The
ampliﬁcation products were cloned into the constitutive
retroviral MLP-E vectors (MSCV-LTR-mir-E-PGK-Puro-
IRES-GFP). After the ligation, Top10 bacteria were
incubated for 15min on ice and then transformed with
the ligation products by heat-shock for 45 s at 42 °C.
Afterward, the bacteria were incubated on ice for 10 min
and then plated on agar plates containing 100 μg/ml
ampicillin. After incubating the plates overnight at 37 °C,
three colonies from each ligation were picked up and
incubated in 2ml lysogeny broth medium as described
before overnight. The plasmids were puriﬁed the next
morning using the QIAprep miniprep DNA Puriﬁcation
Kit (Qiagen, Hilden, Germany). Plasmids containing
correct sequences were used to build the retrovirus in
order to evaluate the knockdown efﬁciency of each pre-
dicted shRNA in NIH/3T3 MEFs. For hydrodynamic tail
vein injections experiments, the shRNAs showing the
highest knockdown efﬁciency were further subcloned into
the pT3-EF1a-GFP-miR-E transposon vector using MAX
Efﬁciency Stbl3 competent cells. The DNA was puriﬁed
with the Qiagen Plasmid Plus Midi Kit or the ZymoPure
Maxiprep Kit (Zymo Research, Irvine, CA, USA).
Retrovirus production, infections and transfections
The retroviruses for evaluating the knockdown efﬁ-
ciency of each single shRNA were produced using the
retrovirus packaging cell line Plat-E (Cell Biolabs, San
Diego, CA, USA). The cells were transfected with 20 μg of
the MLP-E plasmids using the calcium–phosphate pre-
cipitation method. After 48 h, the virus containing med-
ium was ﬁltered (0.45 μm ﬁlter) and supplemented with
4 μg/ml polybrene (Sigma-Aldrich, Taufkirchen, Ger-
many). 3T3 cells were infected under single-copy condi-
tions as previously described46. Brieﬂy, different dilutions
of viral supernatants were used and the transduction
efﬁciency was assessed by measuring the percentage of
GFP-positive cells at 72 h post-infection (Flow cytometry,
Guava Technologies, Chicago, IL, USA). The cells show-
ing <20% of GFP positivity were selected in 4 μg/ml of
puromycin (Sigma-Aldrich, Taufkirchen, Germany) for
3 days.
To generate retrovirus for infecting Hepa1-6, AML12
and HepG2 cells, 293T cells were transfected either with
3 μg of retroviral MLP-E vectors targeting p65, Fas or
control Renilla Luciferase, 3 μg Hit60 and 3 μg pVSV‐G
(ClonTech, Mountain View, CA, USA) using poly-
ethylenimine (PEI) transfection47. The following day,
5 mM butyrate (Sigma‐Aldrich, Taufkirchen, Germany)
was added for 8 h to enhance expression. The super-
natants containing the virus were ﬁltered the next day
(0.45 μm) and frozen in 5 μg/ml polybrene. For infection,
the cells of interest were plated the day before at a 30%
conﬂuence on 12-well plates. The next morning, the cells
were infected with 400 μl of virus supernatant, spun down
for 10min at 400 g and incubated for 6–8 h at 37 °C. This
infection protocol was performed three times followed
Faletti et al. Cell Death and Disease  (2018) 9:909 Page 11 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
by antibiotic selection using 4 μg/ml puromycin for
4 days.
To express a DN from of IκB (S32A/S36A), SV40-
transformed MEFs were seeded in six-well plates (200,000
cells/well) and on the next day transiently transfected with
a mixture of pcDNA3-IκB(S32A/S36A) or the pcDNA3
control vector (1.2 µg) plus 4.5 µl of Attractene (Qiagen,
Hilden, Germany) in 94.3 µl OptiMEM per well. After 24
h, the cells were used for further analysis.
Flow cytometry analysis of Fas cell surface expression
The cells were harvested and washed once in PBS/0.5%
bovine serum albumin (BSA) buffer following an incu-
bation in the same buffer of 1 h with anti-mFas or an IgG1
isotype control antibody conjugated to Alexa Fluor 488
(GFP-negative cells) or PE or APC (GFP-positive cells) (all
at 4 µg/ml, Thermo Fisher, Darmstadt, Germany). The
DNA dye 4,6-diamidino-2-phenylindole (DAPI; 50 µg/ml,
Sigma-Aldrich, Taufkirchen, Germany) was added right
before measurement to exclude dead cells. Flow cyto-
metry analysis was performed using the BD FACS LSRII
and FACSDiva.
Immunohistochemistry and immunoﬂuorescence
Fourteen hours after TNFα or LPS injection, the mice
were euthanized with a CO2 overdose, liver samples were
immediately resected and ﬁxed overnight in 4% paraf-
ormaldehyde (Sigma-Aldrich, Taufkirchen, Germany) in
PBS. The next steps were performed as previously
described48. Brieﬂy, the sections were blocked in 5% BSA/
PBS for 1 h and then incubated overnight in the same
buffer containing one or a combination of the following
primary antibodies: anti-mFas (1 µg/ml, Santa Cruz Bio-
technology, Dallas, TX, USA), anti-p65 (1 µg/ml, Santa
Cruz), anti-GFP (0.5 µg/ml, Abcam, Cambridge, MA,
USA) or rabbit immunoglobulin (1 µg/ml, Dianova,
Hamburg, Germany) as staining control. For immuno-
histochemistry, a biotinylated goat anti-rabbit antibody
diluted 1:200 in antibody dilution buffer was then added
to the sections and incubated in the dark at room tem-
perature for 2 h. The Vectastain ABC kit (Vector Labs,
Burlingame, CA, USA) was used for immunoperoxidase
ampliﬁcation and the ImmPACT DAB (diaminobenzi-
dine) substrate to develop the signal. For immuno-
ﬂuorescence, anti-rabbit-Alexa 594 secondary antibody
for the detection of mFas and p65 and anti-chicken-Alexa
488 for the detection of GFP-positive cells were used
(1 µg/ml, Thermo Fisher Scientiﬁc, Darmstadt, Germany).
After washing the secondary antibodies, the sections were
incubated with Hoechst (1:1000, Sigma-Aldrich, Tauf-
kirchen, Germany) to detect the nuclei and then mounted
with ProLong GOLD mounting medium. The tissue was
imaged with a ﬂuorescent Microscope (Axiovert 40C,
Zeiss, Jena, Germany).
In vivo experiments and hydrodynamic tail vein injections
Eight to 14 weeks old C57BL/6 mice were injected i.p.
with 200 µg of TNFα/kg of body weight or 2 mg of LPS/kg
of body weight and sacriﬁced after 14 h to isolate primary
hepatocytes by liver perfusion or to prepare liver tissue
sections for IHC. Control animals were i.p injected with
PBS. For Fas cell surface, expression analysis isolated
suspension hepatocytes were directly measured without
plating them on collagen.
For hydrodynamic tail vein injections, a solution/
plasmid mix was prepared for each injection containing
20 µg of DNA of pT3-EF1a-GFP-miR-E transposon
vector (containing shp65, shFas or shRenilla) together
with CMV-SB13 Transposase (1:5 ratio) in sterile 0.9%
NaCl49. Eight to 14 weeks old female C57BL/6 mice
were injected with the 0.9% NaCl solution/plasmid mix
into the lateral tail vein with a total volume corre-
sponding to 10% of body weight in 5–7 s. The injections
of each shRNA were performed on three different
days (10 mice for each shRNA). After 5 days, the mice
were i.p injected with PBS or TNFα as mentioned above.
After 14 h, the mice were euthanized with a CO2 over-
dose and the livers resected for immunoﬂuorescence or
anesthetized for the isolation of hepatocytes by col-
lagenase perfusion (each group isolated on three dif-
ferent days).
Acknowledgements
The authors thank Andreas Strasser (Walter and Eliza Hall Institute of Medical
Research, Melbourne, Australia) for the SV40-p65-/- cells and Antonio Mastino
for the pcDNA3-IκB(S32A/S36A) plasmid. This work was supported by the
Federal Ministry of Education and Research through a research grant from the
Virtual Liver Network (FKZ 0315766, FKZ 0315751, FKZ 0315755) (to C.B., L.F.,
S.M.N. and I.M.), by the Spemann Graduate School of Biology and Medicine
(SGBM, GSC 4) and the Excellence Cluster Biological Signaling Studies (BIOSS,
EXC 294), both funded by the Excellence Initiative funded by the German
Research Foundation (DFG) (to C.B), by grant BR-3369/5 of the DFG (to T.B), by
a fellowship from the graduate school RTG1331 (to T.G.), by the Collaborative
Research Centre (SFB) KIDGEM 1140 “Kidney Disease – From Genes to
Mechanisms” of the DFG (to L.P. and C.B.), by the Research Group FOR2036
funded by the DFG (to S.N. and C.B.), by the ERC Consolidator Grant
“CholangioConcept” (to L.Z.), the DFG grants FOR2314, SFB685, SFB/TR209 and
the Gottfried Wilhelm Leibniz Program (to L.Z.).
Author details
1Institute of Molecular Medicine and Cell Research, Faculty of Medicine, Albert
Ludwigs University Freiburg, Stefan Meier Strasse 17, D-79104 Freiburg,
Germany. 2Faculty of Biology, Albert Ludwigs University Freiburg,
Schänzlestrasse 1, D-79104 Freiburg, Germany. 3Spemann Graduate School of
Biology and Medicine (SGBM), Albert Ludwigs University Freiburg, Albertstrasse
19a, D-79104 Freiburg, Germany. 4Biochemical Pharmacology, Department of
Biology, University of Konstanz, Universitätsstrasse 10, D-78457 Konstanz,
Germany. 5Department of Internal Medicine, University Medical Center
Freiburg, Hugstetter Strasse 55, D-79106 Freiburg, Germany. 6Department of
Pharmacology, Biology and Biotechnology, Albert Ludwigs University Freiburg,
Stefan Meier Strasse 19, D-79104 Freiburg, Germany. 7Department of Cancer
Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New
York 10065, USA. 8Department Internal Medicine VIII, University Medical Center
Tübingen, Otfried Müller Strasse 14, D-72076 Tübingen, Germany. 9Department
of Physiology I, Institute of Physiology, Eberhard Karls University Tübingen,
Wilhalmstrasse 56, D-72076 Tübingen, Germany. 10Translational
Gastrointenstinal Oncology Group, German Consortium for Translational
Cancer Research (DKTK), German Cancer Research Center (DKFZ), Im
Faletti et al. Cell Death and Disease  (2018) 9:909 Page 12 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
Neuenheimer Feld 224, D-69120 Heidelberg, Germany. 11BIOSS, Centre for
Biological Signalling Studies, Schänzlestrasse 14, D-79104 Freiburg, Germany.
12Present address: Institute of Physiology, University of Zürich,
Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. 13Present address:
Department of Molecular and Cell Biology, University of California, Berkeley, CA
94720, USA. 14Present address: Helmholtz Group Cell Plasticity and Epigenetic
Remodeling, German Cancer Research Center (DKFZ) & Institute of Pathology,
University Hospital, Im Neuenheimer Feld 224, D-69120 Heidelberg, Germany
Authors' contributions
C.B., U.M., I.M., T.B., S.L. and L.Z. conceived the project. L.F., S.S., L.P., S.N., T.G.,
S.M.N., C.-H.H., T.-W.K., F.H., L.D. and D.T. performed experiments, L.F. and L.P.
prepared the ﬁgures and L.F. and C.B. wrote the manuscript.
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41419-018-0935-9).
Received: 21 June 2018 Revised: 30 July 2018 Accepted: 1 August 2018
References
1. Leithauser, F. et al. Constitutive and induced expression of APO-1, a new
member of the nerve growth factor/tumor necrosis factor receptor super-
family, in normal and neoplastic cells. Lab. Invest. 69, 415–429 (1993).
2. Ni, R. et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes.
Exp. Cell Res. 215, 332–337 (1994).
3. Ogasawara, J. et al. Lethal effect of the anti-Fas antibody in mice. Nature 364,
806–809 (1993).
4. Galle, P. R. et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in
liver damage. J. Exp. Med. 182, 1223–1230 (1995).
5. Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent
features of human nonalcoholic steatohepatitis. Gastroenterology 125,
437–443 (2003).
6. Ibuki, N. et al. In situ expression of granzyme B and Fas-ligand in the liver of
viral hepatitis. Liver 22, 198–204 (2002).
7. Rivero, M. et al. Apoptosis mediated by the Fas system in the fulminant
hepatitis by hepatitis B virus. J. Viral Hepat. 9, 107–113 (2002).
8. Ryo, K. et al. Signiﬁcance of Fas antigen-mediated apoptosis in human ful-
minant hepatic failure. Am. J. Gastroenterol. 95, 2047–2055 (2000).
9. Natori, S. et al. Hepatocyte apoptosis is a pathologic feature of human alco-
holic hepatitis. J. Hepatol. 34, 248–253 (2001).
10. Fox, C. K., Furtwaengler, A., Nepomuceno, R. R., Martinez, O. M. & Krams, S. M.
Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis.
Liver 21, 272–279 (2001).
11. Strand, S. et al. Hepatic failure and liver cell damage in acute Wilson’s disease
involve CD95 (APO-1/Fas) mediated apoptosis. Nat. Med. 4, 588–593 (1998).
12. Varfolomeev, E. E. & Ashkenazi, A. Tumor necrosis factor: an apoptosis JuNKie?
Cell 116, 491–497 (2004).
13. Micheau, O. & Tschopp, J. Induction of TNF receptor I-mediated apoptosis via
two sequential signaling complexes. Cell 114, 181–190 (2003).
14. Chu, Z. L. et al. Suppression of tumor necrosis factor-induced cell death by
inhibitor of apoptosis c-IAP2 is under NF-kappa B control. Proc. Natl Acad. Sci.
USA 94, 10057–10062 (1997).
15. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. & Baldwin, A. S. NF-
kappa B antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2
to suppress caspase-8 activation. Science 281, 1680–1683 (1998).
16. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K. & Tschopp, J. NF-kappa B
signals induce the expression of c-FLIP. Mol. Cell. Biol. 21, 5299–5305 (2001).
17. Pahl, H. L. Activators and target genes of Rel/NF-kappa B transcription factors.
Oncogene 18, 6853–6866 (1999).
18. Leist, M. et al. Murine hepatocyte apoptosis induced in vitro and in vivo by
TNF-alpha requires transcriptional arrest. J. Immunol. 153, 1778–1788 (1994).
19. Morikawa, A. et al. Apoptotic cell death in the response of D-galactosamine-
sensitized mice to lipopolysaccharide as an experimental endotoxic shock
model. Infect. Immun. 64, 734–738 (1996).
20. Josephs, M. D. et al. Lipopolysaccharide and D-galactosamine-induced hepatic
injury is mediated by TNF-alpha and not by Fas ligand. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 278, R1196–R1201 (2000).
21. Kaufmann, T. et al. Fatal hepatitis mediated by tumor necrosis factor TNF alpha
requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity
30, 56–66 (2009).
22. Nelson, D. R. et al. Activation of tumor necrosis factor-alpha system in chronic
hepatitis C virus infection. Dig. Dis. Sci. 42, 2487–2494 (1997).
23. Spengler, U. et al. Serum levels and in situ expression of TNF-alpha and TNF-
alpha binding proteins in inﬂammatory liver diseases. Cytokine 8, 864–872
(1996).
24. McClain, C. J., Song, Z. Y., Barve, S. S., Hill, D. B. & Deaciuc, I. Recent advances in
alcoholic liver disease - IV. Dysregulated cytokine metabolism in alcoholic liver
disease. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G497–G502 (2004).
25. Minagawa, M., Deng, Q. G., Liu, Z. X., Tsukamoto, H. & Dennert, G. Activated
natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha
during alcohol consumption. Gastroenterology 126, 1387–1399 (2004).
26. Costelli, P. et al. Mice lacking TNF alpha receptors 1 and 2 are resistant to
death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell
Death Differ. 10, 997–1004 (2003).
27. Frankel, S. K. et al. TNF-alpha sensitizes normal and ﬁbrotic human lung
ﬁbroblasts to Fas-induced apoptosis. Am. J. Respir. Cell Mol. Biol. 34, 293–304
(2006).
28. Schmich, K. et al. Tumor necrosis factor alpha sensitizes primary murine
hepatocytes to Fas/CD95-induced apoptosis in a Bim- and Bid-dependent
nanner. Hepatology 53, 282–292 (2011).
29. Ouaaz, F., Li, M. & Beg, A. A. A critical role for the RelA subunit of nuclear factor
kappa B in regulation of multiple immune-response genes and in Fas-induced
cell death. J. Exp. Med. 189, 999–1004 (1999).
30. Lewis, N. R., Pallis, M. & Russell, N. H. Fas receptor-Fas ligand system is inde-
pendent of both CD34 status and chemosensitivity in acute myeloid leuke-
mia. Exp. Hematol. 28, 535–542 (2000).
31. Galenkamp, K. M. O. et al. TNF alpha sensitizes neuroblastoma cells to FasL-,
cisplatin- and etoposide-induced cell death by NF-kappa B-mediated
expression of Fas. Mol. Cancer 14, 62, https://doi.org/10.1186/s12943-015-
0329-x (2015).
32. Chan, H., Bartos, D. P. & Owen-Schaub, L. B. Activation-dependent transcrip-
tional regulation of the human fas promoter requires NF-kappa B p50-p65
recruitment. Mol. Cell. Biol. 19, 2098–2108 (1999).
33. Kuhnel, F. et al. NFkappaB mediates apoptosis through transcriptional
activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 275,
6421–6427 (2000).
34. Fellmann, C. et al. An optimized microRNA backbone for effective single-copy
RNAi. Cell Rep. 5, 1704–1713 (2013).
35. Pelossof, R. et al. Prediction of potent shRNAs with a sequential classiﬁcation
algorithm. Nat. Biotechnol. 35, 350–353 (2017).
36. Bell, J. B. et al. Preferential delivery of the Sleeping Beauty transposon system
to livers of mice by hydrodynamic injection. Nat. Protoc. 2, 3153–3165 (2007).
37. Matsuki, Y. et al. Soluble Fas gene therapy protects against Fas-mediated
apoptosis of hepatocytes but not the lethal effects of Fas-induced TNF-alpha
production by Kupffer cells. Cell Death Differ. 9, 626–635 (2002).
38. Bennett, M. et al. Cell surface trafﬁcking of Fas: a rapid mechanism of p53-
mediated apoptosis. Science 282, 290–293 (1998).
39. Sodeman, T., Bronk, S. F., Roberts, P. J., Miyoshi, H. & Gores, G. J. Bile salts
mediate hepatocyte apoptosis by increasing cell surface trafﬁcking of Fas. Am.
J. Physiol. Gastrointest. Liver Physiol. 278, G992–G999 (2000).
40. Ghosh, S. & Karin, M. Missing pieces in the NF-kappa B puzzle. Cell 109,
S81–S96 (2002).
41. Kucharczak, J., Simmons, M. J., Fan, Y. J. & Gelinas, C. To be, or not to be: NF-
kappa B is the answer - role of Rel/NF-kappa B in the regulation of apoptosis.
Oncogene 22, 8961–8982 (2003).
42. Saccani, S., Pantano, S. & Natoli, G. Two waves of nuclear factor kappaB
recruitment to target promoters. J. Exp. Med. 193, 1351–1359 (2001).
43. Chien, Y. C. et al. Control of the senescence-associated secretory phenotype
by NF-kappa B promotes senescence and enhances chemosensitivity. Genes
Dev. 25, 2125–2136 (2011).
Faletti et al. Cell Death and Disease  (2018) 9:909 Page 13 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
44. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S. & Baltimore, D. Embryonic
lethality and liver degeneration in mice lacking the RelA component NF-
kappa B. Nature 376, 167–170 (1995).
45. Klingmuller, U. et al. Primary mouse hepatocytes for systems biology
approaches: a standardized in vitro system for modelling of signal transduc-
tion pathways. Syst. Biol. (Stevenage). 153, 433–447 (2006).
46. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras
provokes premature cell senescence associated with accumulation of p53 and
p16INK4a. Cell 88, 593–602 (1997).
47. Soneoka, Y. et al. A transient three-plasmid expression system for the pro-
duction of high titer retroviral vectors. Nucleic Acids Res. 23, 628–633
(1995).
48. Jakob, S., Corazza, N., Diamantis, E., Kappeler, A. & Brunner, T. Detection of
apoptosis in vivo using antibodies against caspase-induced neo-epitopes.
Methods 44, 255–261 (2008).
49. Huang, C. H. et al. CDK9-mediated transcription elongation is required for MYC
addiction in hepatocellular carcinoma. Genes Dev. 28, 1800–1814 (2014).
Faletti et al. Cell Death and Disease  (2018) 9:909 Page 14 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
